New Delhi, Aug 14 (PTI) Pharma major Lupin Ltd on Monday said it has received approval from the US health regulator to market its generic antibiotic Doxycycline Hyclate delayed-release tablets used to treat bacterial infections.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Doxycycline Hyclate delayed-release tablets of strengths 50 mg, 60 mg, 75 mg, 80 mg, 100 mg, 120 mg, 150 mg, and 200 mg, Lupin said in a regulatory filing.

Also Read | Independence Day 2023: Know Flag Code of India and How to Hoist and Dispose of Tiranga With Full Respect As Per Government Guidelines.

This product will be manufactured at Lupin's Pithampur facility in India, it added.

Doxycycline Hyclate Delayed-Release tablets had estimated annual sales of USD 9 million in the US, the company said citing IQVIA MAT June 2023 data.

Also Read | Thane Hospital Deaths: 18 Patients Including Women Died in Past 24 Hours at Chhatrapati Shivaji Maharaj Hospital in Kalwa; Probe Panel Constituted, Says TMC Chief Abhijit Bangar (Watch Video).

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)